Rosamaria Lappano

List of Publications by Year
in descending order

87	5,543	87888 38	79698 73
papers	citations	h-index	g-index

89	89	89	6412
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment. Cancers, 2022, 14, 539.	3.7	8
2	A Review on the Antimicrobial Activity of Schiff Bases: Data Collection and Recent Studies. Antibiotics, 2022, 11, 191.	3.7	120
3	Triple-negative breast cancer drug resistance, durable efficacy, and cure: how advanced biological insights and emerging drug modalities could transform progress. Expert Opinion on Therapeutic Targets, 2022, 26, 513-535.	3.4	6
4	Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression. Cancers, 2021, 13, 645.	3.7	29
5	Activation of the S100A7/RAGE Pathway by IGF-1 Contributes to Angiogenesis in Breast Cancer. Cancers, 2021, 13, 621.	3.7	22
6	DDR1 Affects Metabolic Reprogramming in Breast Cancer Cells by Cross-Talking to the Insulin/IGF System. Biomolecules, 2021, 11, 926.	4.0	9
7	Estrogen receptor variant ERÎ±46 and insulin receptor drive in primary breast cancer cells growth effects and interleukin 11 induction prompting the motility of cancerâ€associated fibroblasts. Clinical and Translational Medicine, 2021, 11, e516.	4.0	3
8	Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells. Cells, 2021, 10, 3145.	4.1	14
9	The FGF/FGFR System in Breast Cancer: Oncogenic Features and Therapeutic Perspectives. Cancers, 2020, 12, 3029.	3.7	54
10	Computational Approaches for the Discovery of GPER Targeting Compounds. Frontiers in Endocrinology, 2020, 11, 517.	3.5	16
11	The IL1Î²-IL1R signaling is involved in the stimulatory effects triggered by hypoxia in breast cancer cells and cancer-associated fibroblasts (CAFs). Journal of Experimental and Clinical Cancer Research, 2020, 39, 153.	8.6	43
12	Newly Synthesized Imino-Derivatives Analogues of Resveratrol Exert Inhibitory Effects in Breast Tumor Cells. International Journal of Molecular Sciences, 2020, 21, 7797.	4.1	21
13	Cytotoxic, Anti-bacterial, and Wound-healing Activity of Prenylated Phenols from the Kurdish Traditional Medicinal Plant Onobrychis Carduchorum (Fabaceae). Planta Medica International Open, 2020, 07, e106-e113.	0.5	2
14	Microenvironmental Determinants of Breast Cancer Metastasis: Focus on the Crucial Interplay Between Estrogen and Insulin/Insulin-Like Growth Factor Signaling. Frontiers in Cell and Developmental Biology, 2020, 8, 608412.	3.7	16
15	The G Protein-Coupled Estrogen Receptor (GPER) Expression Correlates with Pro-Metastatic Pathways in ER-Negative Breast Cancer: A Bioinformatics Analysis. Cells, 2020, 9, 622.	4.1	28
16	Interaction of the Anti-Proliferative GPER Inverse Agonist ERÎ±17p with the Breast Cancer Cell Plasma Membrane: From Biophysics to Biology. Cells, 2020, 9, 447.	4.1	8
17	Cancer associated fibroblasts: role in breast cancer and potential as therapeutic targets. Expert Opinion on Therapeutic Targets, 2020, 24, 559-572.	3.4	42
18	IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells. Cells, 2020, 9, 1010.	4.1	58

#	Article	IF	Citations
19	DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop. Endocrine-Related Cancer, 2019, 26, 197-214.	3.1	38
20	AHR and GPER mediate the stimulatory effects induced by 3-methylcholanthrene in breast cancer cells and cancer-associated fibroblasts (CAFs). Journal of Experimental and Clinical Cancer Research, 2019, 38, 335.	8.6	32
21	The Peptide ERÎ±17p Is a GPER Inverse Agonist that Exerts Antiproliferative Effects in Breast Cancer Cells. Cells, 2019, 8, 590.	4.1	17
22	GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells Toward Breast Tumor Progression. Cells, 2019, 8, 223.	4.1	41
23	Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 58.	8.6	60
24	A novel functional crosstalk between DDR1 and the IGF axis and its relevance for breast cancer. Cell Adhesion and Migration, 2018, 12, 1-10.	2.7	24
25	GPER is involved in the functional liaison between breast tumor cells and cancer-associated fibroblasts (CAFs). Journal of Steroid Biochemistry and Molecular Biology, 2018, 176, 49-56.	2.5	39
26	miR-338-3p Is Regulated by Estrogens through GPER in Breast Cancer Cells and Cancer-Associated Fibroblasts (CAFs). Cells, 2018, 7, 203.	4.1	25
27	GPCR Modulation in Breast Cancer. International Journal of Molecular Sciences, 2018, 19, 3840.	4.1	35
28	The Physiopathological Role of the Exchangers Belonging to the SLC37 Family. Frontiers in Chemistry, 2018, 6, 122.	3.6	29
29	miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling. Journal of Experimental and Clinical Cancer Research, 2018, 37, 94.	8.6	49
30	Functional characterization of the partially purified Sac1p independent adenine nucleotide transport system (ANTS) from yeast endoplasmic reticulum. Journal of Biochemistry, 2018, 164, 313-322.	1.7	16
31	GPER, IGFâ€IR, and EGFR transduction signaling are involved in stimulatory effects of zinc in breast cancer cells and cancerâ€associated fibroblasts. Molecular Carcinogenesis, 2017, 56, 580-593.	2.7	43
32	Composition, Antifungal and Antiproliferative Activities of the Hydrodistilled Oils from Leaves and Flower Heads of Pterocephalus nestorianus N<scp>Ã¡bÄ›lek</scp>. Chemistry and Biodiversity, 2017, 14, e1700009.	2.1	7
33	Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. Drugs, 2017, 77, 951-965.	10.9	17
34	The lauric acid-activated signaling prompts apoptosis in cancer cells. Cell Death Discovery, 2017, 3, 17063.	4.7	79
35	Recent views of heavy metals as possible risk factors and potential preventive and therapeutic agents in prostate cancer. Molecular and Cellular Endocrinology, 2017, 457, 57-72.	3.2	42
36	Recent advances on the stimulatory effects of metals in breast cancer. Molecular and Cellular Endocrinology, 2017, 457, 49-56.	3.2	39

#	Article	IF	Citations
37	Highly Cytotoxic Xanthones from Cratoxylum cochinchinense Collected in Myanmar. Natural Product Communications, 2017, 12, 1934578X1701201.	0.5	5
38	G Protein-Coupled Receptors at the Crossroad between Physiologic and Pathologic Angiogenesis: Old Paradigms and Emerging Concepts. International Journal of Molecular Sciences, 2017, 18, 2713.	4.1	27
39	GPER mediates the angiocrine actions induced by IGF1 through the HIF-1Î±/VEGF pathway in the breast tumor microenvironment. Breast Cancer Research, 2017, 19, 129.	5.0	59
40	A genetic polymorphism repurposes the G-protein coupled and membrane-associated estrogen receptor GPER to a transcription factor-like molecule promoting paracrine signaling between stroma and breast carcinoma cells. Oncotarget, 2017, 8, 46728-46744.	1.8	30
41	GPER is involved in the regulation of the estrogen-metabolizing CYP1B1 enzyme in breast cancer. Oncotarget, 2017, 8, 106608-106624.	1.8	25
42	Stimulatory actions of IGF-I are mediated by IGF-IR cross-talk with GPER and DDR1 in mesothelioma and lung cancer cells. Oncotarget, 2016, 7, 52710-52728.	1.8	35
43	Response to â€œComment on â€˜Effects of Atrazine on Estrogen Receptor Î±â€“ and G Proteinâ€“Coupled Receptor 30â€“Mediated Signaling and Proliferation in Cancer Cells and Cancer-Associated Fibroblastsâ€™â€•. Environmental Health Perspectives, 2016, 124, A65.	6.0	0
44	GPER signalling in both cancer-associated fibroblasts and breast cancer cells mediates a feedforward IL1Î²/IL1R1 response. Scientific Reports, 2016, 6, 24354.	3.3	64
45	Macromolecular Modelling and Docking Simulations for the Discovery of Selective GPER Ligands. AAPS Journal, 2016, 18, 41-46.	4.4	30
46	Recent Advances on the Role of G Protein-Coupled Receptors in Hypoxia-Mediated Signaling. AAPS Journal, 2016, 18, 305-310.	4.4	23
47	The G protein estrogen receptor (GPER) is regulated by endothelin-1 mediated signaling in cancer cells. Cellular Signalling, 2016, 28, 61-71.	3.6	23
48	GPER is involved in the stimulatory effects of aldosterone in breast cancer cells and breast tumor-derived endothelial cells. Oncotarget, 2016, 7, 94-111.	1.8	57
49	IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway. Oncotarget, 2016, 7, 7683-7700.	1.8	69
50	Copper activates HIF-1Î±/GPER/VEGF signalling in cancer cells. Oncotarget, 2015, 6, 34158-34177.	1.8	128
51	A calixpyrrole derivative acts as a GPER antagonist: mechanisms and models. DMM Disease Models and Mechanisms, 2015, 8, 1237-46.	2.4	32
52	Effects of Atrazine on Estrogen Receptor Î± â€“ and G Proteinâ€“Coupled Receptor 30â€“Mediated Signaling and Proliferation in Cancer Cells and Cancer-Associated Fibroblasts. Environmental Health Perspectives, 2015, 123, 493-499.	6.0	64
53	(6-Bromo-1,4-dimethyl-9<i>H</i>-carbazol-3-yl-methylene)-hydrazine (Carbhydraz) Acts as a GPER Agonist in Breast Cancer Cells. Current Topics in Medicinal Chemistry, 2015, 15, 1035-1042.	2.1	27
54	Different 6-Aryl-Fulvenes Exert Anti-proliferative effects on Cancer Cells. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 468-474.	1.7	12

#	Article	IF	Citations
55	GPER Function in Breast Cancer: An Overview. Frontiers in Endocrinology, 2014, 5, 66.	3.5	82
56	GPER Mediates Activation of HIF1Î±/VEGF Signaling by Estrogens. Cancer Research, 2014, 74, 4053-4064.	0.9	105
57	GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts. Endocrine-Related Cancer, 2014, 21, 739-753.	3.1	37
58	Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth. Breast Cancer Research and Treatment, 2014, 146, 273-285.	2.5	87
59	Niacin activates the G protein estrogen receptor (GPER)-mediated signalling. Cellular Signalling, 2014, 26, 1466-1475.	3.6	42
60	New titanocene derivatives with high antiproliferative activity against breast cancer cells. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 136-140.	2.2	19
61	Estrogen Signaling. , 2014, , 1-4.		0
62	Estrogen Signaling. , 2014, , 1637-1640.		0
63	Synthesis, characterization and cytotoxic activity on breast cancer cells of new half-titanocene derivatives. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3458-3462.	2.2	38
64	HIF-1Î±/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs). Breast Cancer Research, 2013, 15, R64.	5.0	173
65	Cross-talk between GPER and growth factor signaling. Journal of Steroid Biochemistry and Molecular Biology, 2013, 137, 50-56.	2.5	73
66	Bisphenol A Induces Gene Expression Changes and Proliferative Effects through GPER in Breast Cancer Cells and Cancer-Associated Fibroblasts. Environmental Health Perspectives, 2012, 120, 1177-1182.	6.0	234
67	GPCRs and cancer. Acta Pharmacologica Sinica, 2012, 33, 351-362.	6.1	85
68	G Protein-coupled Estrogen Receptor Mediates the Up-regulation of Fatty Acid Synthase Induced by 17Î²-Estradiol in Cancer Cells and Cancer-associated Fibroblasts. Journal of Biological Chemistry, 2012, 287, 43234-43245.	3.4	87
69	MIBE acts as antagonist ligand of both estrogen receptor Î± and GPER in breast cancer cells. Breast Cancer Research, 2012, 14, R12.	5.0	81
70	New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. Cellular Signalling, 2012, 24, 1515-1521.	3.6	63
71	Unraveling the Role of GPER in Breast Cancer. , 2012, , 115-127.		0
72	Rhenium(iv) compounds inducing apoptosis in cancer cells. Chemical Communications, 2011, 47, 5283.	4.1	35

#	Article	IF	Citations
73	The Cholesterol Metabolite 25-Hydroxycholesterol Activates Estrogen Receptor Î±-Mediated Signaling in Cancer Cells and in Cardiomyocytes. PLoS ONE, 2011, 6, e16631.	2.5	94
74	G protein-coupled receptors: novel targets for drug discovery in cancer. Nature Reviews Drug Discovery, 2011, 10, 47-60.	46.4	629
75	Multifactorial Regulation of GPER Expression in Cancer Cells and Cardiomyocytes. Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 2011, 11, 235-242.	0.5	2
76	Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer. Current Molecular Pharmacology, 2011, 4, 167-175.	1.5	49
77	E-cadherin mediates the aggregation of breast cancer cells induced by tamoxifen and epidermal growth factor. Breast Cancer Research and Treatment, 2010, 121, 79-89.	2.5	9
78	SLC37A1 Gene expression is up-regulated by epidermal growth factor in breast cancer cells. Breast Cancer Research and Treatment, 2010, 122, 755-764.	2.5	32
79	Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells. Molecular and Cellular Endocrinology, 2010, 320, 162-170.	3.2	106
80	G Protein-Coupled Receptor 30 Expression Is Up-Regulated by EGF and TGFÎ± in Estrogen Receptor Î±-Positive Cancer Cells. Molecular Endocrinology, 2009, 23, 1815-1826.	3.7	121
81	Structureâ€“activity relationships of resveratrol and derivatives in breast cancer cells. Molecular Nutrition and Food Research, 2009, 53, 845-858.	3.3	47
82	Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO Journal, 2009, 28, 523-532.	7.8	283
83	Epidermal Growth Factor Induces G Protein-Coupled Receptor 30 Expression in Estrogen Receptor-Negative Breast Cancer Cells. Endocrinology, 2008, 149, 3799-3808.	2.8	131
84	The Novel Estrogen Receptor, G Protein-Coupled Receptor 30, Mediates the Proliferative Effects Induced by 17Î²-Estradiol on Mouse Spermatogonial GC-1 Cell Line. Endocrinology, 2008, 149, 5043-5051.	2.8	147
85	A sexually dimorphic distribution pattern of the novel estrogen receptor G-protein-coupled receptor 30 in some brain areas of the hamster. Journal of Endocrinology, 2007, 196, 131-138.	2.6	43
86	G Proteinâ€“Coupled Receptor 30 (GPR30) Mediates Gene Expression Changes and Growth Response to 17Î²-Estradiol and Selective GPR30 Ligand G-1 in Ovarian Cancer Cells. Cancer Research, 2007, 67, 1859-1866.	0.9	383
87	17Î²-Estradiol, Genistein, and 4-Hydroxytamoxifen Induce the Proliferation of Thyroid Cancer Cells through the G Protein-Coupled Receptor GPR30. Molecular Pharmacology, 2006, 70, 1414-1423.	2.3	269